Instylla Announces Enrollment of Initial Patient in the Prospective Multicenter “HALT” Study
Pivotal study to evaluate Embrace™ Hydrogel Embolic System for the embolization of arterial bleeds in the peripheral vasculature BEDFORD, Mass., Jan. 10, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular…
Comments Off on Instylla Announces Enrollment of Initial Patient in the Prospective Multicenter “HALT” Study